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Abstract: Current pharmacotherapy of chronic obstructive pulmonary disease (COPD)
aims at reducing respiratory symptoms and exacerbation frequency. Effective therapies to
reduce disease progression, however, are still lacking. Furthermore, COPD medications
showed less favorable effects in emphysema than in other COPD phenotypes. Elastin fibers
are reduced and disrupted, whereas collagen levels are increased in emphysematous lungs.
Protease/antiprotease imbalance has historically been regarded as the sole cause of emphy-
sema. However, it is nowadays appreciated that emphysema may also be provoked by
perturbations in the sequential repair steps following elastolysis. Essentiality of fibulin-5
and lysyl oxidase-like 1 in the elastin restoration process is discussed, and it is argued that
copper deficiency is a plausible reason for failing elastin repair in emphysema patients.
Since copper-dependent lysyl oxidases crosslink elastin as well as collagen fibers, copper
supplementation stimulates accumulation of both proteins in the extracellular matrix.
Restoration of abnormal elastin fibers in emphysematous lungs is favorable, whereas
stimulating pulmonary fibrosis formation by further increasing collagen concentrations
and organization is detrimental. Heparin inhibits collagen crosslinking while stimulating
elastin repair and might therefore be the ideal companion of copper for emphysema
patients. Efficacy and safety considerations may lead to a preference of pulmonary admin-
istration of copper-heparin over systemic administration.
Keywords: collagen, copper, desmosine, elastin, emphysema, fibulin-5, heparin, lysyl
oxidase, lysyl oxidase-like protein 1, tropoelastin
Introduction
Emphysema is defined as dilatation and/or destruction of airspaces distal to terminal
bronchioles.1 Chronic obstructive pulmonary disease (COPD), on the other hand, is a
condition characterized by persistent respiratory symptoms in combination with air-
flow limitation at spirometry.2 Although emphysema is considered to be a subtype of
COPD,2 emphysematous lesions on computed tomography (CT) may also be detected
in nonobstructive subjects.3
Inhaled bronchodilators, whether or not combined with corticosteroids, form the
mainstay of pharmacotherapy for COPD.2 These drugs are primarily intended to
relieve symptoms and reduce exacerbation frequency with little if any effect on
attenuation of disease progression.2 Furthermore, current therapy seems to be less
effective in patients with emphysema than in those with other COPD phenotypes.4,5
The objective of this manuscript is to provide a theoretical rationale for a poten-
tially novel disease-modifying therapy for emphysema patients to decelerate disease
progression and reverse structural changes.
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Given the low perfusion/ventilation ratio of the usually
most damaged upper lung zones,6 inhalation therapy may
be preferred over systemic routes of drug administration to
optimize delivery to emphysematous areas. Another advan-
tage of local therapy is that it requires lower doses of
medicine, which reduces the risk of systemic side-effects.
Causes Of Emphysema
A long time after the discovery that genetic deficiency of
the antiprotease α-1 antitrypsin has the ability to induce
premature emphysema, the protease/antiprotease imbal-
ance remains the prevailing paradigm as the monocausal
explanation for all forms of emphysema. Chronic inhala-
tion of tobacco smoke is the most prevalent risk factor of
emphysema, which may negatively modulate the afore-
mentioned equilibrium by both upregulating protease and
downregulating antiprotease activity.7,8 Various lines of
evidence suggest that disturbances of repair mechanisms
in the lungs may also be causes of emphysema.9–12
Elastin And Collagen
The pulmonary parenchyma is that portion of the lungs
involved in gas transfer and consists of alveoli, respiratory
bronchioles and capillaries. Lung parenchymal cells are
encompassed by a three-dimensional network of extracel-
lular matrix. Fibrillar collagens (type I, II, III, Vand XI) and
elastin are the most abundant proteins in the pulmonary
extracellular matrix.13,14 Elastin has unique elastic
properties,14 facilitating deformability of the pulmonary
compartment during the breathing cycle, and collagen pro-
vides lungs with tensile strength.13 Elastin fibers are abnor-
mal in pulmonary parenchyma of patients with emphysema
due to a combination of proteolytic degradation and ineffi-
cacious repair. Most studies found decreased absolute elas-
tin concentrations in emphysematous lungs.15–18 Some
early reports did not find such a reduction;19,20 however,
validity of their methods to quantify elastin has been
questioned.17 Collagen levels are increased in emphysema-
tous alveolar walls of patients with moderate COPD, which
is further enhanced in those with very severe airflow
limitation.15 However, the organization/maturation level
of collagen type I is reduced in both airways and parench-
yma of patients with COPD.21–23
Emphysematous remodeling of the extracellular matrix
may have detrimental physiological consequences, i.e.,
airflow limitation as well as static and dynamic hyperin-
flation, leading to shortness of breath and exercise
limitation.6 Elastin content in alveolar walls positively
relates to spirometric values,16 whereas the reverse is
true with regard to alveolar collagen.15
Modulatory treatments for patients with emphysema
should suppress collagen accumulation and stimulate repair
of disrupted elastin fibers. Development of completely new
elastin fibers may not always be advantageous. This is illu-
strated by pulmonary elastin levels that are increased in
patients with idiopathic pulmonary fibrosis (IPF) but also
inversely associated with both lung function tests and
survival.24
Elastogenesis And Elastin Repair
Elastic fiber formation in the lungs is usually restricted to
early life.25 The largest and main part of elastic fibers
consists of elastin, which organizes itself into a network
of crosslinked polymers through a series of intricate
sequential steps (Figure 1).14 In short, (a) elastin’s precur-
sor tropoelastin is produced within mesenchymal cells and
secreted into the extracellular matrix, (b) tropoelastin pro-
teins then undergo a process of spontaneous self-aggrega-
tion (i.e., coacervation), (c) tropoelastin polymers are
subsequently attached to a pre-deposited scaffold of micro-
fibrils and (d) are finally crosslinked with other tropoelas-
tin polymers into mature elastic fibers.
Although there are some important differences, repair
steps in response to proteolytic elastolysis are rather simi-
lar to those of initial elastogenesis.10,11,26,27
Lysyl Oxidase And Lysyl Oxidase-
Like Proteins
Prototype lysyl oxidase (LOX) and LOX-like (LOXL)
proteins 1 to 4 form a superfamily of metalloenzymes
produced by fibroblasts.28 They catalyze the process of
elastin crosslinking by oxidizing lysine amino acids into
highly reactive allysine residues (Figure 1). Subsequently,
three allysines and one untransformed lysine on adjacent
tropoelastin polymers spontaneously react into stable end-
products, e.g., desmosine and isodesmosine, that are exclu-
sively present in elastic fibers.29
LOX enzymes are also involved in the crosslinking
process of collagen, which gives rise to various crosslinks
that can also be found in elastic fibers.30
Fibulins
Fibulins form a seven-membered group of secreted proteins
that facilitate interactions between extracellularmatrix proteins
and components of basal membranes.31 Fibulin-4 and
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fibulin-5, in particular, play nonredundant roles in multiple
steps of elastic tissue formation. Although their actions seem
to be rather comparable, fibulin-4 and fibulin-5 are unable to
replace or compensate each other.10 The preferential binding
between prototype LOX and fibulin-4 is crucial for elastin
crosslinking in the initial phase of elastogenesis,26,27 whereas
LOXL1/fibulin-5 interactions have similar pivotal functions
during elastin restoration later in life.10,11
Convergence And Divergence
Between Fibulin-5 And Lysyl
Oxidase-Like Protein 1 During
Elastin Repair
Protease activity does not lead to permanent loss of pul-
monary elastic fibers and emphysema formation as long as
damage is instantly and properly repaired.32 Numerous
genes coding for proteins involved in elastin restoration
processes, such as elastin and fibulin-5, are among the
strongest upregulated loci in lungs of patients with
COPD.33,34 Intratracheal administration of elastases pro-
duces an initial rapid formation of emphysema, followed
by a phase of elastin repair in which pulmonary expression
of fibulin-5 and elastin is enhanced.35,36 These studies sug-
gest that both humans and animals try to repair damaged
elastin fibers after proteolytic insults in an attempt to pre-
vent irreversible emphysematous destruction.33–36
The relevance of fibulin-5 in the pathogenesis of emphy-
sema, through its role in the elastin repair process, has been
illustrated in various studies.10,35 For instance, fibulin-5
knock-out mice survive to adulthood but not without devel-
oping severe lung emphysema.10 Furthermore, individuals
with loss of function mutations in the fibulin-5 gene develop
cutis laxa,37 a disease that is characterized by inelastic skin
and with emphysema as a frequent manifestation.38
Successful elastin restoration also depends on proper func-
tion of LOX enzymes and particularly of LOXL1.
Administration of a pan-LOX inhibitor has been shown to
exacerbate elastase-induced emphysema formation,9 and
mice in which LOXL1 was knocked-out developed a compar-
able emphysematous phenotype as when switching off fibulin-
5.10,11 These data underscore the importance of LOXL1 in
emphysema formation. However, in contrast to fibulin-5,33
LOXL1 activity is not upregulated but downregulated in
patients with emphysema.39 The reason for this difference
may well lay in the fact that LOXL1, unlike fibulin-5, depends
on a cofactor, i.e., copper.40 Whereas synthesis of repair pro-
teins can be autonomically upregulated following proteolytic
insults, tissues are dependent on exogenous supply to provide
them with extra copper.
Figure 1 Tropoelastin monomers (1) aggregate into polymers (2). Lysine is transformed by copper-dependent lysyl oxidase (LOX-Cu2+) into highly reactive allysine (3).
Three allysines and one untransformed lysine on adjacent fibers spontaneously condense into one (iso)desmosine amino acid (depicted as a hexagon; 4).
Dovepress Janssen et al
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Animal Models Of Copper
Deficiency-Induced Emphysema
Low pulmonary copper levels have been acknowledged
for more than forty years to possess emphysema-inducing
potency in animals.41–45 Copper deficiency may lead to
both developmental41,43 and acquired emphysema.44
Protease levels are not significantly elevated in models
of copper deficiency;44 however, histologic appearance of
emphysematous lesions in copper-deficient animals is
similar to those provoked by intratracheal administration
of elastases.42,46 These findings illustrate that emphysema
in copper deficiency is mainly caused by failing elastogen-
esis and/or elastin repair mechanisms and not because of
protease/antiprotease imbalance.
Emphysema Induced By Copper-Deficient
Diets In Rodents
Pregnant rats and hamsters were separated into groups that
were made copper-deficient through dietary means and
control arms that received regular nutrition.41,43 The
mothers’ diet was also fed to newborns after weaning.
Postmortem examination revealed that extensive bullous
emphysematous changes had developed in lungs of copper-
deficient rodents.41,43 Alveolar internal surface area was
reduced as a reflection of damage to alveoli, and airspaces in
the remaining fairly normal-appearing lung areas were
enlarged. Pressure–volume curves of copper-deficient animals
shifted upwards and leftwards due to, respectively, lung hyper-
inflation and increased compliance.
Changes In Pulmonary Extracellular Matrix Of
Copper-Deficient Rats
Elastin concentration in the lungs was significantly reduced by
17%, whereas collagen levels remained stable.41
After a period of being fed a copper-deficient diet,
some 5–10 weeks old rats were repleted with copper to
assess reversibility of emphysematous lesions. Pulmonary
elastin density and ultrastructure returned to near normal.
However, no effect of repletion was found on alveolar
size. This suggests that copper-induced developmental
emphysema is partially but not fully reversible.
Changes In Pulmonary Extracellular Matrix Of
Copper-Deficient Hamsters
Pulmonary (iso)desmosine levels were slightly, though
significantly, increased in copper-deficient compared to
copper-sufficient hamsters.43 This finding is not only
opposite to what would have been anticipated but is also
contradictory to the decreased desmosine levels that were
found in copper-deficient chicks.47 A reason for this lack
of decreased elastin-crosslinks in experimental hamsters
could have a methodological basis, since (iso)desmosine
in biological samples can only be reliably quantified with
liquid chromatography-tandem mass spectrometry (LC-
MS/MS).29 For example, capillary electrophoresis com-
bined with laser-induced fluorescence – which is a more
sophisticated method to assess (iso)desmosine than the
amino acid analyzer method used by Soskel et al43 –
measured about 100-times higher desmosine levels in
plasma of patients with emphysema induced by α1-anti-
trypsin deficiency than LC-MS/MS.48,49 This illustrates
the problem that techniques other than LC-MS/MS lack
the specificity to differentiate (iso)desmosine-crosslinks
from other elastin-derived peptides.29
LOX activity was assessed, and although no significant
difference (i.e., p = 0.125) was found between groups,
LOX activity in relation to the total weight of proteins
tended to be lower in copper-deficient (269 cpm/mg pro-
tein) than in copper-sufficient (335 cpm/mg protein) ham-
sters. Before discarding this statistically nonsignificant
decrease as irrelevant, one should realize that concentra-
tions of maintenance proteins other than LOX are not
lower but higher in emphysematous lungs.33 Decreased
expression of LOX mRNA was found in a rat model of
copper deficiency-induced emphysema, whereas fibulin-5
mRNA concentrations were increased.44 This pattern of
gene expression in copper-deficient rats reminisces to
upregulation of fibulin-5 and downregulation of LOX
enzymes in human COPD lungs.33,39
Given that copper is also the essential cofactor of the
cytosolic enzyme superoxide dismutase (SOD), activity of
this protein was quantified as well.43 In contrast to LOX,
SOD activity was significantly diminished in the copper-
deficient lungs. Soskel et al therefore explained the para-
dox of low pulmonary copper levels but not significantly
decreased LOX activity by ascribing emphysema forma-
tion in hamsters to reduced activity of SOD rather than
of LOX.
We argue that it would have been more appropriate if
LOXL1 would have been specifically quantified, as hamsters
were sacrificed at the age of 8 to 10 weeks.43 Initial elastogen-
esis in rodent lungs – in which LOX plays a major role – is
practically completed within the first two weeks after birth.50
Subsequent pulmonary elastin metabolism progresses slowly
in the ensuing months50 and involves LOXL1 rather than
LOX.11 Whether the LOX-activity assay that was applied by
Janssen et al Dovepress
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Soskel et al reflects either only prototype or pan-LOX activity
has never been assessed.43,51,52
Contrary to in hamsters,43 LOX activity was signifi-
cantly reduced in lungs of copper-deficient chicks.45 A
potential reason for the more pronounced difference in
LOX activity between copper-deficient and control chicks
might be that the birds were, unlike the rodents,43 still in a
developmental state (i.e. 23-days-old) in which LOX
rather than LOXL1 played a pivotal role.45
Given issues with the methods that were used, this hamster
model43 should ideally be repeated in order to quantify (iso)
desmosine as well as LOXL1 protein, mRNA and activity
levels with contemporary technologies.
Emphysema Induced By Copper-
Deficient/Zinc-Supplemented Diet In
Porcine
Whereas copper is LOX’s essential cofactor, zinc has an
inhibitory effect on the enzyme’s activity.53 Pigs were
therefore raised on a copper-deficient/zinc-supplemented
diet in order to induce emphysema.42
Perforated alveolar walls were observed in lungs of
animals who had received the copper-deficient diet. The
lungs demonstrated features of emphysema such as air-
space enlargement, decrease in alveolar surface areas and
increased compliance.
Elastin levels in the lungs remained similar between cop-
per-deficient/zinc-supplemented and control pigs. The degree
of elastin crosslinkingwas not assessed; however, we suspect a
reduction of (iso)desmosine in lungs of copper-deficient/zinc-
supplemented pigs. In contrast to elastin, collagen was signifi-
cantly increased in lung tissues from the experimental
animals.42 A plausible explanation for this divergent reaction
of collagen and elastin to copper deficiency might be that
collagen’s resistance to proteolytic degradation is less depen-
dent on LOX-mediated crosslinking than elastin. This is prob-
ably because non-enzymatic crosslinks from glycated amino
acid residues are more prevalent in collagen than elastic
fibers,54which also confer someprotection against proteases,55
whereas tropoelastin monomers are instantaneously degraded
if they are not enzymatically crosslinked by LOX.56
Cellular Aspects Of Emphysema Induced
By Copper-Deficient Diet Combined
With Copper Chelator
Male rats received a copper-deficient diet in combination with
administration of a copper chelator (i.e., tetrathiomolybdate).44
Themicroscopic examination of lung sections showed emphy-
sematous destruction with enlargement of the alveoli.
Based on the pulmonary downregulation of both LOX
and vascular endothelial growth factor (VEGF) gene expres-
sion, it was suggested that copper-deficient rats not only
acquire emphysema due to extracellular processes but also
via cellular mechanisms. The relevance of VEGF-downre-
gulation in the pathogenesis of emphysema has been estab-
lished in animal studies demonstrating that lowering either
expression or activity of this growth factor induces emphy-
sematous changes.57,58 Mizuno et al hypothesized that cop-
per depletion causes detachment of alveolar cells from their
supporting matrix, which may result in a form of pro-
grammed cell death named anoikis.44,59 The authors subse-
quently sought evidence for this theory and found support by
demonstrating reduced FAK, AKT and ERK1/2 phosphory-
lation patterns as well as enhanced expression of caspase-8
and p53 genes, which can all be regarded as indicative for
anoikis activity.44 This specific form of apoptosis may poten-
tially form a mechanistic link between copper-induced fail-
ure of maintenance processes in the extracellular matrix and
reduced cellularity of emphysematous lungs.
Copper Deficiency Causes Emphysema,
But Does Emphysema Induce Copper
Deficiency?
Models using various animal species have unequivocally
demonstrated that copper deficiency has the potential to
cause emphysema.41–45 However, there is also an animal
model to suggest that this mechanism may also work the
other way around, namely that emphysema formation
induces pulmonary copper deficit.60
Transgenic mice with lung-specific TNF-α overexpres-
sion were used as a model for emphysema.60 A variety of
metal and micronutrient concentrations were measured in
various tissues. Pulmonary zinc and selenium concentra-
tions did not significantly vary between mice with normal
and overexpressed TNF-α. However, a 75% decline of
copper concentrations was found in lungs of TNF-α over-
expressing compared to age-matched wild-type mice,
whereas copper levels remained fairly stable in blood
and other organs. Importantly, this pattern of isolated
pulmonary copper deficiency seems to be also present in
human COPD.61,62
mRNA levels of LOXL1 – as an enzyme that is more
important for elastin maintenance than prototype LOX11 –
were unfortunately not quantified. However, expression of
Dovepress Janssen et al
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the gene coding for LOX was significantly downregulated in
TNF-α overexpressing animals. We suspect that the follow-
ing sequential steps may have led to pulmonary copper
deficiency in these transgenic animals (Figure 2). High pul-
monary TNF-α levels attract macrophages and neutrophils to
the lungs, which produce proteolytic enzymes that accelerate
elastolysis. Damage to pulmonary elastic fibers increases the
need for elastin repairing proteins as well as for copper to
activate additional LOX enzymes. Contrary to animalmodels
of emphysema induced by copper-deficient diets,41–45 copper
supply to the lungs will not be reduced in TNF-α overexpres-
sing mice.60 Normal pulmonary copper levels, however, may
be insufficient when massive elastin repair is required. Such
increased demand for copper may induce copper deficiency
and reduce levels of activated LOX(L), hampering elastin
restoration. Since partially degraded elastin has enhanced
vulnerability to further proteolytic degradation,63 failing
elastin restoration due to copper deficiency may provoke a
vicious circle of elastolysis (Figure 2).
The concept of expenditure-induced deficit of cofac-
tors, rather than primary deficiency, has been demonstrated
in other pathological circumstances. Administration of
vitamin D, for example, promotes vascular mineralization
as well as synthesis of the vitamin K-dependent calcifica-
tion inhibitor matrix Gla protein.64,65 The need for vitamin
K to activate surplus matrix Gla protein consequently
increases, which will induce vitamin K-deficiency if
demand outstrips supply. Similar to vitamin K’s ability to
prevent vitamin D-induced calcification, we suggest that
copper supplementation may interrupt the vicious circle of
emphysema formation (Figure 2).
There might be an alternative explanation for reduced
LOX activation yet sufficient circulating levels of copper in
emphysematous lungs. The import of copper from the
extracellular matrix into cells is facilitated by copper trans-
porter 1 (Ctr1),66 which occurs as either full-length or
truncated protein.67 The latter exhibits about 50% reduced
capacity for copper uptake compared to the full-length
variant.67 Truncated Ctr1 is generated through cleavage of
full-length Ctr1 by cathepsin proteases.68 Since activity of
these proteolytic enzymes is upregulated in patients with
COPD,69 it is plausible that cleavage of Ctr1 is enhanced in
emphysematous lungs leading to reduced intracellular cop-
per availability for LOX activation.
The most relevant remaining questions that need to be
answered in future animal studies are whether smoking-
induced emphysema induces copper deficiency and
whether pulmonary copper deficiency amplifies the devel-
opment of smoking-induced emphysema.
Human Data Suggesting That
Copper Deficiency Induces
Emphysema
Whether deficiency of copper relates to the development
of emphysema in humans is currently unknown; however,
some data may provide a rationale to explore this
possibility.39,62
Copper In Exhaled Breath Condensate
Collecting exhaled breath condensate (EBC) is a noninva-
sive method to sample the airways. EBC of stable COPD
patients contains lower copper levels than of controls, and
copper levels in EBC are positively related to forced
expiratory volume in one second (FEV1) in individuals
with COPD.62
It is tempting, though highly speculative, to suggest
that low copper levels in EBC – as a reflection of pulmon-
ary copper status – may lead to reduced spirometric values
through prevention of LOX(L) activation.
Importantly, no differences were found in EBC copper
levels between different FEV1-based stages of disease
severity.62 It might be that low pulmonary copper levels
play a role in the initiation rather than the progression of
COPD.
Emphysema As A Potential Complication
Of Menkes Disease
Menkes disease is a lethal genetic disorder characterized
by neurological deterioration in combination with connec-
tive tissue abnormalities. Emphysema may be a complica-
tion of Menkes disease.70,71 The syndrome is caused by
mutations in Menkes P-type ATPase (ATP7A) gene coding
for an intracellular copper-transporter.72 Inherited dysfunc-
tion of ATP7A is also the reason why so-called Blotchy
mice develop early emphysema.73 Cells with mutant pro-
teins on their surfaces are unable to take up copper in cells,
which precludes activation of LOX by copper leading to
inefficacious elastin development and restoration pro-
cesses. Copper supplementation therapy cannot negate
this,70 since copper is intracellularly incorporated into
LOX proteins.74
A patient with Menkes disease has been described who
developed respiratory distress from about 9 months of
age.70 CT revealed bilateral emphysematous blebs, and
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Figure 2 Smoking induces inflammation, which is associated with enhanced proteolytic activity leading to accelerated elastin degradation. Damage to elastic fibers
upregulates synthesis of elastin repair proteins and increases copper demand to activate additional LOXL1 enzymes. This may deplete copper stores, which may lead to
decreased LOXL1 activity and impaired elastin repair. Cigarette smoke also has direct inhibitory effects on LOXL1 activity. A vicious circle of elastolysis and copper depletion
may arise (bold arrows), as partially degraded elastin is more accessible to proteases than intact fibers. Copper supplementation may provide an escape from the vicious
circle by activating LOXL1 and facilitating efficacious elastin repair (dashed arrows). Green=positive effect, yellow=neutral effect and red=negative effect.
Dovepress Janssen et al
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chest X-rays demonstrated lung hyperinflation which pro-
gressed over several months. He died at 14 months of age.
Postmortem examination of the lungs demonstrated severe
and diffuse panlobular emphysema in combination with
various-sized bullae.
Although the link between disrupted copper metabo-
lism and emphysema formation in Menkes disease is inter-
esting from a pathogenic standpoint, it is important to
realize that there are fundamental differences between
this genetic disorder and smoking-related emphysema.
Lysyl Oxidase Enzymes In Nongenetic
Human Emphysema
Levels of copper-activated LOX, LOXL1 and LOXL2
were decreased in emphysematous compared to none-
mphysematous lung samples obtained from COPD patients
who had undergone surgical lung cancer resection.39
Postoperative pathological examination confirmed the
diagnosis of lung cancer in 87.5% of the cases. It is
important to appreciate that LOX enzymes seem to be
also involved in tumorigenesis.72 No data are currently
available to answer the question whether LOX activity is
also decreased in emphysematous lungs without concomi-
tant lung cancer.
Copper metabolism domain containing-1 (COMMD1)
is a protein that regulates cellular copper concentration
through regulation of export from cells to the extracellular
matrix,75 and its levels appear to be reduced in human
emphysematous lung tissue.39 The authors attributed their
findings of low activated LOX levels to decreased copper
concentrations in the pulmonary extracellular matrix
caused by depletion of COMMD1.39 However, this
seems unlikely since copper incorporation into LOX is
not an extracellular but intracellular process72 and
COMMD1 is not a regulator of cellular copper uptake.
Reduced levels of activated LOX, LOXL1 and LOXL2
proteins in affected areas39 may nevertheless suggest local
copper deficiency in lungs of patients with emphysema,
however, via other mechanisms than reduction in the level
of COMMD1.
Smoking, Copper And Inhibition Of
Lysyl Oxidase
Cigarette smoke is the single most important risk factor for the
development of emphysema.76 Smokers usually first develop
emphysematous lesions in the middle portion of secondary
pulmonary lobules (i.e., centrilobular emphysema),77 probably
because that is where inhaled particles deposit. Tobacco-
derived toxins may interfere with LOX crosslinking, and con-
sequently with elastin repair, through several mechanisms.
Increased Copper Demand
The smoking-induced inflammatory response associates
with increased recruitment of protease-producing leuko-
cytes to the lungs, resulting in acceleration of elastin
degradation. Increased elastolysis subsequently upregu-
lates restoration processes and thereby the need for copper
to activate additional LOX enzymes. Tobacco inhalation
may potentially deplete pulmonary copper ions through
this mechanism (Figure 2).60
Inhibition Of Lysyl Oxidase By Nicotine
And/Or Cadmium
Another reason why inhalation of cigarette smoke may
hamper LOX crosslinking is by its dose-dependent
decreasing effect on LOX levels and activity.78 Tobacco
contains a myriad of harmful chemicals, of which nicotine
and cadmium are the most likely candidates to be respon-
sible for the inhibitory effect of smoke condensate on LOX
enzymes.79–81
Nicotine seems to have the capacity to chelate metals,
which is exemplified by its reducing effect on copper
levels in senile plaques.82 Exposure of pregnant rats to
nicotine results in the development of panlobular emphy-
sema in their offspring,80 which is largely undone by
maternal copper supplementation.79 These results suggest
that a chelating effect of nicotine exposure leads to inade-
quate copper concentrations to activate sufficient LOX
enzymes for elastogenesis and that this effect can be
reversed by administrating additional copper.
Whereas cadmium is undetectable in human tissues at
birth, its concentrations gradually increase over time due
to intake levels that exceed levels of excretion.83 Inhaled
tobacco constitutes a significant source of cadmium expo-
sure for smoking individuals.84 Postmortem examination
demonstrated about three times higher hepatic cadmium
concentrations in subjects with COPD compared to non-
obstructive controls.85 Pulmonary cadmium levels are also
elevated in emphysema patients compared to individuals
with healthy lungs.86 Nebulizing rats with cadmium chlor-
ide results in dilation, distortion and destruction of alveoli
in such a pattern that lesions resemble human centrilobular
emphysema.81 Remarkably, short-term exposure to cad-
mium induces upregulation of LOX, whereas chronic
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exposure reduces LOX levels.87,88 Similar to nicotine-
mediated LOX-inhibition,79 copper supplementation also
neutralizes cadmium-mediated LOX-inhibition.89,90
The influence of cigarette smoke on LOX is rather com-
plex as tobacco leaves also contain copper,91,92 which may
potentially stimulate pulmonary LOX activity.93,94 Although
plasma copper levels are elevated in smokers compared to
nonsmokers,95 the net effect of cigarette smoke extract on
LOX is – as discussed in the above – inhibitory.78
Expert Opinion
We consider the gene expression study of Brandsma et al
as a landmark study since it was the first to demonstrate
that repair mechanisms are strongly upregulated in lungs
of regular COPD patients.33 What we are bound to ask is
why this effort is not successful, as the answer to this
question may be key to establish modulatory pharma-
cotherapy for patients with emphysema in order to effica-
ciously restore pulmonary proteolytic damage.
Rationale For Copper Inhalation Therapy
In Emphysema
Based on presence of pulmonary copper deficiency yet
normal circulating copper levels in TNF-α overexpressing
transgenic mice60 and the suggestion that lung-specific
deficiency of copper is also present in patients with
COPD,61,62 the possibility of using topical lung supple-
mentation of copper was proposed as a novel treatment
strategy for individuals with emphysema in order to
restore pulmonary copper levels and thereby local elastin
repair capacity.60 Although we agree that this concept
should be further explored, we also foresee major limita-
tions as various animal models have demonstrated adverse
side effects of inhaled copper monotherapy.96–99
It is to be kept in mind that copper-dependent LOX
enzymes are not only elastin but also collagen crosslinkers.
The formation of crosslinks promotes organization, stabili-
zation and accumulation of collagen, which are hallmarks
of fibrosis. Whereas the organization of collagen fibrils is
reduced in COPD lungs,21–23 collagen maturation is
enhanced in lung parenchyma of patients with IPF.100 This
difference in collagen organization may well be due to the
level of enzymatic crosslinking by LOX enzymes. Both
animal and human data suggest that particularly the degree
of pulmonary LOXL1 activity is decisive for whether or not
fibrotic lung disease develops. LOXL1 knock-out mice
are protected against pulmonary fibrosis induced by
overexpression of the profibrotic cytokine transforming
growth factor-β1,101 whereas levels of LOXL1 are
increased in lungs of patients with IPF (Figure 3) and
associate with the thickness of collagen fibers.102 The
effects of inhaled copper oxide nanoparticles were studied
in mice, and it was found that they stimulated pulmonary
collagen accumulation culminating in lung fibrosis.97 The
fact that copper-chelator tetrathiomolybdate proved protec-
tive against bleomycin-induced lung fibrosis corroborates
the existence of mechanistic links between high pulmonary
copper levels, collagen accumulation and fibrosis
formation.96 We expect that inhalation therapy with copper
in emphysema patients would cause a shift from emphyse-
matous towards fibrotic parenchymal lung disease.
Heparin Added To Inhalation
Formulations With Copper
Heparin is a glycosaminoglycan and has the highest nega-
tive charge density per disaccharide of any known biolo-
gical molecule. We propose that heparin should be added
to inhalation formulations with copper for various reasons
(Table 1; Figure 4).
Heparin As Specific Inhibitor Of Collagen
Crosslinking And Fibrosis Formation
Heparin is a ligand of both collagen and elastin, however, its
effect on LOX-mediated crosslinking is fundamentally differ-
ent for both proteins. In vitro experiments demonstrate that
heparin – when present prior to collagen fibrillogenesis –
strongly inhibits collagen crosslinking, which reduces
Figure 3 Immunohistochemistry image of an explant lung from a patient with
combined pulmonary fibrosis and emphysema showing increased lysyl oxidase-like
protein 1 (LOXL1) levels in fibrotic areas and decreased LOXL1 levels in emphy-
sematous areas (brown=LOXL1; blue=nucleus; pink=cytoplasm).
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collagen stabilization and thereby the occurrence offibrosis.103
The antifibrotic effect of heparin also seems to be relevant in
lungs of mammals as experiments show that aerosolized
heparin prevents bleomycin-induced fibrosis in rabbits by
reducing pulmonary collagen and hydroxyproline-crosslink
contents.104 We therefore propose that heparin is the ideal
companion of copper in inhalation formulations to prevent
copper-induced maturation and further accumulation of col-
lagen fibrils in emphysematous lungs.
Heparin As Promotor Of Tropoelastin
Polymerization And Elastin Repair
The second step of elastogenesis is the aggregation of tro-
poelastin monomers into continuous layers of polymerized
fibers (Figure 1).14 Heparin, as a strong anionic molecule, has
the ability to facilitate this process of self-assembly by
neutralizing positively charged amino acids of tropoelastin
proteins and to thereby undo the repellent effect that similar
charged tropoelastin proteins have on each other.105
Calculations suggest that the negative charge of heparin is
approximately in balance with the positive charge of
tropoelastin.105
Heparin As Ideal Copper-Carrier With Regard To
Elastin Repair
Heparin may not only be the ideal companion of copper in
inhalation formulations because of its inhibitory properties
on collagen crosslinking and synergistic effect on elastin
repair but may have more potential advantageous properties.
A study assessing the ability of copper to induce
angiogenesis in the cornea suggested that copper ions are
in need for a carrier to reduce toxicity and potentiate
Table 1 Reasons For Adding Heparin To Copper Inhalation Formulations
Property Mechanism References
Stimulating elastin repair Facilitating self-assembly of tropoelastin monomers into polymers by neutralizing positively
charged amino acids
[105]
Preventing fibrosis formation Inhibiting lysyl oxidase-mediated collagen crosslinking and thereby organization,
stabilization and accumulation of collagen
[103,104]
Reducing copper dose and thereby
risk of copper toxicity
Retaining copper ions in the lungs by being taken up and stored in macrophages and potentially
also by interacting with positively charged components of the airways and airspaces
[105,109,110]
Figure 4 Inhalation therapy with copper stimulates elastin repair by activating LOXL1. Inhaled copper monotherapy, however, also stimulates lung fibrosis formation by
stimulating collagen crosslinking, stabilization and accumulation. Furthermore, high-dose copper is needed when administered as monotherapy, since unbound copper rapidly
passes the alveolar-capillary membrane. This increases the risk of extrapulmonary copper toxicity. Addition of heparin retains copper in the pulmonary compartment, which
makes that lower copper doses suffice. Heparin also has an inhibitory effect on collagen crosslinking while stimulating elastin repair by promoting aggregation of tropoelastin.
Green=positive effect, yellow=neutral effect and red=negative effect.
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activity.106 Both copper chloride and copper sulfate mono-
therapies were only angiogenic at dosages that induced
inflammatory responses, whereas copper bound to either
ceruloplasmin or heparin was effective at nontoxic doses.
The fact that unbound copper ions do not only have such
adverse side effects in eyes but also in lungs was sug-
gested by studies in which inhaled copper oxide upregu-
lated pulmonary expression of major proinflammatory
genes,97,98 as well as the number of macrophages, neutro-
phils and lymphocytes in bronchoalveolar lavage fluid
(BALF).99
Although ceruloplasmin is the natural copper-carrier in
the blood, heparin might be the ideal chaperone for copper
with regard to pulmonary elastin repair. Heparin, at least in
vitro, preferentially binds to positively charged lysine resi-
dues in tropoelastin proteins.105 It may thereby deliver
copper ions to the sites where they are needed most,
such as free margins of proteolytically destructed alveoli,
where elastogenesis is particularly taking place.36
Exchange of copper for other cations, from heparin mole-
cules, may subsequently provide local LOXL1-producing
cells with copper.
Heparin As A Retainer Of Copper In The Lungs
Copper ions do not remain in the pulmonary compartment
for extended periods of time following inhalation but
rapidly pass the alveolar-capillary membrane to enter the
circulation.97 The fast clearance from the lungs implies
that relatively high copper doses are needed to achieve the
intended local therapeutic effect. This is problematic given
that the fibrotic effect of copper on lung tissue is dose-
dependent.97 High-dose copper inhalation therapy will also
have a significant incremental effect on circulating levels
of copper, which is unwanted as it increases the risk for
cerebral and hepatic copper toxicity.107,108
In contrast to copper, heparin is retained in the lungs
for days after inhaled administrations,109,110 which makes
that up to 400,000 international units (I.U.) of heparin
(resulting in a delivery dose of 32,000 I.U. to the lower
respiratory tract) can be safely nebulized,111 whereas 5000
I.U. are intravenously used as a bolus to initiate antic-
oagulation therapy. Almost 40% of the inhaled heparin
dose that initially deposits in the lower respiratory tract
remains in the lungs after 24 hrs,109 and a single nebuliza-
tion session with heparin (moderately) affects systemic
coagulation in human volunteers for up to two weeks.110
Heparin is taken up and stored by macrophages without
being degraded, and it is only released upon death of the
storage cell.110 Furthermore, it is to be expected that
inhaled heparin will make interactions with various posi-
tively charged components of the airways and airspaces,
such as lysine amino acid residues in elastic fibers,105
which may provide another mechanism to prevent heparin
molecules from directly entering the systemic circulation.
The addition of heparin to copper inhalation formula-
tions may be the key to retain copper within lungs and
thereby achieve efficacious LOXL activation with minimal
risk of copper toxicity.
Tolerability Of Copper
Copper is an essential nutrient and it has been estimated
that a daily intake of 0.75 mg would maintain copper
balance in a stable 70-kg adult.112 A double-blinded
study assessed effects of 10 mg copper per day, as copper
gluconate, and found no change on either copper concen-
trations in serum, urine or hair.113 Levels of hematocrit,
triglycerides, cholesterol and liver function tests were also
unaltered.
The safe upper limits of population mean intakes have
been set on 10 mg/day for women and 12 mg/day for
men.114 Significantly lower doses may be sufficient for
activation of LOX enzymes by means of pulmonary cop-
per-heparin administration.
Copper-Heparin Inhalation Therapy
Given that copper ions carry double positive charges (Cu2+),
copper-heparin ionic interactions will arise when they are com-
bined with sodium-heparin in a solution.115 A maximum of 23
to 24 copper ions can be bound to one heparin molecule.115
Copper ions display initial site-specific coordinated binding to
heparin,116 which is distinct from connections that heparin
makes with other cations.117 Electrostatic interaction with cop-
per ions induces subtle conformational changes to heparin
loosening its helical structure.115,117 We assessed whether vary-
ing heparin and copper concentrations affect nebulization char-
acteristics of aerosolized copper-heparin solutions, which does
not appear to be the case (Table 2). We therefore assume that it
is acceptable to extrapolate published 99mtechnetium-labeled
sodium-heparin (99mTc-heparin) data to predict pulmonary
deposition distribution of copper-heparin solutions.
Deposition of inhaled 99mTc-heparin has been quanti-
fied in the airways and airspaces of healthy subjects after a
single nebulization.109 Of note, 99mTc-labeling does not
have a modulatory effect on the deposition pattern of
nebulized heparin. Less than 15% of the nebulizer charge
reaches the mouth and 7.6% reaches the lower respiratory
Dovepress Janssen et al
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tract. The level of nebulized heparin that deposits in the
lungs seems to be remarkably low; however, it is compar-
able to deposition rates after nebulization of β2-agonists
with a jet nebulizer.118
Airspaces in the lung apices are typically most severely
affected in patients with smoking-induced emphysema.77
Nearly 50% of the heparin dose that arrives at the pul-
monary compartment deposits in the upper lung zones and
about one-third in the periphery, which suggests that neb-
ulization is a suitable method to reach emphysematous
lung areas. Based on 99mTc-heparin distribution propor-
tions, combined with the fact that one mole copper is
needed for the activation of one mole LOX, we are able
to estimate nebulizer-charging doses to deliver required
amounts of copper-heparin in order to activate certain
quantities of LOX enzymes in target zones.
It has to be taken into account that a large proportion of
nebulized copper-heparin solution will deposit in the small
airways <2 mm in internal diameter, which are affected in
the early stages of COPD.119–121 Copper-heparin might
potentially also have advantageous effects in this part of
the lungs, given that levels of collagen and elastin are,
respectively, increased and decreased in both airways and
parenchyma of patients with COPD.15,16
Five-Year View
The effects of inhalation therapy with copper-heparin
should first be tested in animal models of TNF-α over-
expression-, elastase- and smoking-induced emphysema,
where mean linear intercept and alveolar surface area
should be used as endpoints. Micro CT-scanning could
also be applied as a sophisticated technique to quantify
emphysema and fibrosis formation. Furthermore, pulmon-
ary levels of copper, (tropo)elastin, collagen, (iso)desmo-
sine, hydroxyproline and gene expression of maintenance
proteins should be assessed as well as LOX(L) protein and
activity levels. Copper should also be measured in serum,
liver and brains to assess the effect of copper-heparin inha-
lation therapy on extrapulmonary copper concentrations.
Next, the effect of a single copper-heparin nebuliza-
tion on systemic copper and coagulation levels should be
studied in healthy volunteers to assess safety and toler-
ability. High-dose inhalation therapy with heparin has
been proven safe in healthy volunteers as well as in
COPD and IPF patients,111,122,123 and the intended copper
dose (i.e., somewhere between 0.1 and 1.0 mg/day) is far
beneath the safe upper limit of daily intake.114 Adverse
side-effects related to inhaled copper-heparin are there-
fore not expected.
If proven safe and tolerable, a clinical trial of a few
weeks should be conducted in emphysema patients to
assess the effects of copper-heparin nebulization on
(tropo)elastin, (iso)desmosine, hydroxyproline and
LOXL1 levels in BALF. Desmosines only occur in
elastic fibers from which they can be released by
proteases.124 Their levels in BALF therefore specifi-
cally reflect the rate of elastolysis in the lungs. As
partially degraded elastic fibers have increased suscept-
ibility for proteolytic degradation63 and inhaled copper
supplementation is supposed to enhance elastin repair
in the lungs by activating pulmonary LOXL1,94 we
would expect a decreasing effect of the proposed treat-
ment on BALF (iso)desmosine levels.
If inhalation treatment with nebulized copper-heparin
formulations proves efficacious in animal and human stu-
dies, more convenient and efficacious (i.e., lower loading
doses to achieve equal concentrations in the lower respira-
tory tract) copper-heparin inhalation forms, such as dry-
powder formulations, should be developed.
We hope that within five years copper-heparin inhala-
tion therapy has been explored as modulatory treatment for
patients with emphysema to repair proteolytic lung
damage.
Table 2 Particle Size Distribution Of Nebulized Copper-Heparin Solutions
Cu2+ Heparin X10 X50 X90 Particles <5μm
0.5 mg 5000 I.U. 0.81 μm 2.34 μm 6.58 μm 82.44%
0.80 μm 2.29 μm 6.34 μm 83.58%
1.0 mg 100,000 I.U. 0.80 μm 2.32 μm 6.86 μm 82.13%
0.80 μm 2.33 μm 7.05 μm 81.19%
Notes: The first nebulizing solution consisted of 26 mg (5000 IU) heparin sodium and 1.25 mg copper sulfate (CuSO4; 0.5 mg copper) dissolved in 5 mL saline. The second
nebulizing solution consisted of 5 mL saline plus 524 mg (100,000 IU) heparin and 2.5 mg CuSO4 (1.0 mg copper). Formulations were loaded into a reusable nebulizer (PARI
LC® Plus) and nebulized with a compressor (PARI BOY® SX). The aerosols were analyzed every 30 second in duplicate by laser diffraction analysis using a HELOS BR laser
diffractometer in combination with the INHALER system (Sympatec, Germany) until the nebulizer started to sputter.
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Conclusions
Emphysema is a very common respiratory disorder for which
no regenerating therapy is currently available. Besides pro-
tease/antiprotease imbalance, disturbances in the mainte-
nance of elastin may also cause emphysema. LOXL1 is a
copper-dependent enzyme that plays a crucial step in the
restoration of proteolytic damage to elastic fibers. We spec-
ulate that local availability of copper is the rate-limiting step
in the pulmonary elastin repair process. Copper inhalation
therapy may be a valid therapeutic option for patients with
emphysema; however, inhaled copper monotherapy is asso-
ciated with stimulation of collagen accumulation and fibrosis
formation. Heparin may be the ideal companion of copper for
various reasons: i.e., (a) stimulating elastin repair, (b) inhibit-
ing collagen crosslinking and (c) reducing copper toxicity by
extending copper retention time in the lungs and thereby
reducing the required copper dose in inhalation formulations.
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